Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) is among the fundamentally strong penny stocks to invest in. Analysts at H.C. Wainwright have reiterated their Buy rating on Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) while maintaining a price target of $2, implying an upside of over 900%. This overwhelming optimism stems from the company’s comprehensive portfolio update just a few days ago.
While focusing on the clinical development of its leading candidate, NGC-Cap, Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) has also started to initiate an adaptive pivotal Phase 3 study for PCS499 to address underserved kidney areas based on preliminary positive results and FDA approval of surrogate endpoints. With such a vision in mind, there is no doubt the company can actually exceed analyst expectations.
A syringe filled with a biopharmaceutical drug product on a light blue background.
On top of that, Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) has entered into a binding term sheet with privately held Intact Therapeutics, enabling it to receive $454 million in milestone payments, a 12% royalty on future sales, and a 3.5% equity stake in Intact. The exclusivity of its PCS12852 prokinetic agent for gastroparesis and other gastrointestinal motility disorders positions PCSA well to lead the market.
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) is a Maryland-based clinical-stage biopharmaceutical company that develops chemotherapy drugs to enhance the efficacy of cancer treatment. Incorporated in 2017, the company adopts a “Regulatory Science Approach” to more effectively lead its pipeline programs.
While we acknowledge the potential of PCSA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
